Gainers

• SciSparc (NASDAQ:SPRC) stock rose 35.1% to $5.2 during Thursday's pre-market session. The market value of their outstanding shares is at $19.5 million.
• Codexis (NASDAQ:CDXS) stock increased by 27.55% to $1.62. The market value of their outstanding shares is at $114.7 million. As per the press release, Q4 earnings came out yesterday.
• Aethlon Medical (NASDAQ:AEMD) shares increased by 16.92% to $1.93. The market value of their outstanding shares is at $2.1 million.
• Agape ATP (NASDAQ:ATPC) shares moved upwards by 13.62% to $4.74. The market value of their outstanding shares is at $4.1 million.
• Incannex Healthcare (NASDAQ:IXHL) shares increased by 11.89% to $6.68. The market value of their outstanding shares is at $71.3 million.
• Lunai Bioworks (NASDAQ:LNAI) shares moved upwards by 11.3% to $0.21. The market value of their outstanding shares is at $4.5 million.

Losers

• Jin Medical International (NASDAQ:ZJYL) stock declined by 19.2% to $0.12 during Thursday's pre-market session. The company's market cap stands at $22.2 million.
• SCWorx (NASDAQ:WORX) shares declined by 15.62% to $0.12. The market value of their outstanding shares is at $2.3 million.
• SILO Pharma (NASDAQ:SILO) stock fell 13.54% to $0.32. The market value of their outstanding shares is at $4.8 million.
• Serina Therapeutics (AMEX:SER) shares fell 10.0% to $1.35. The market value of their outstanding shares is at $16.1 million.
• Rapid Micro Biosystems (NASDAQ:RPID) shares declined by 9.11% to $3.98. The market value of their outstanding shares is at $194.1 million. As per the press release, Q4 earnings came out today.
• P3 Health Partners (NASDAQ:PIII) stock decreased by 8.71% to $2.83. The company's market cap stands at $10.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.